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Breast cancer is the second most common malignancy in the world, accounting for over 1.7 
million new diagnoses and an estimated 500,000 deaths per year (1). Overexpression of the receptor 
tyrosine kinase ErbB2, also known as Her2 or Neu, occurs in over 30% of breast cancers and correlates 
with metastasis, poor prognosis, and decreased survival (1, 2). Although therapeutics targeting ErbB2 
show clinical efficacy, many patients display no initial response or develop drug resistance over time 
(2). A deeper understanding of the molecular basis of ErbB2-driven tumorigenesis is thus required for 
the development of improved therapeutic strategies. 
In vitro experiments suggest that activation of the c-Jun NH2-terminal kinase (JNK) pathway, a 
mitogen-activated protein kinase pathway, promotes proliferation, cellular invasion, and stem cell 
expansion in ErbB2-driven breast cancer (3, 4). Furthermore, unpublished data from our lab using 
mammary epithelial cells expressing activated ErbB2 show that JNK is required for acinus formation in 
in vitro 3D cultures. In contrast to these studies showing a tumorigenic role for the JNK pathway, other 
data from our lab show that JNK loss results in accelerated breast tumor growth, suggesting a tumor 
suppressive role (5, 6). However, these studies were performed in p53 knockout mice with or without a 
Kras mutation, where the latter required extensive aging and genomic instability to occur before 
differences in tumor growth were observable. To date, limited in vivo studies exist to confirm the role of 
JNK in more biologically relevant breast tumor models, such as in ErbB2-mediated cancer, which 
accounts for over 30% of all human breast cancers. In addition, the molecular mechanisms by which 
JNK signaling promotes ErbB2-driven tumorigenesis remains poorly understood.  
To address the discrepancy in JNK function between the in vitro ErbB2-driven breast cancer 
data and the in vivo p53 knockout tumor data, I began the development of an in vivo murine model to 
confirm the role of JNK in ErbB2-driven breast cancer. This mouse model will also allow us to test a 
potential mechanism by which JNK regulates tumorigenesis. Studies show that ErbB2-mediated 
secretion of the inflammatory cytokine IL6 promotes transformation and tumor growth by activation of 
the STAT3 transcription factor, triggering an IL6/STAT3 autocrine signaling loop (7,8). A major 
regulator of Il6 gene expression includes activator protein 1 (AP-1), a transcription factor composed of 
downstream JNK targets in the Jun protein family (9). In vitro experiments using ErbB2-
overexpressing mammary epithelial cell lines show that chemical inhibition of JNK suppresses 
secreted IL6 protein levels, supporting a role for the JNK pathway in IL6 regulation (7). Thus, I 
hypothesize that JNK drives ErbB2-driven breast cancer by promoting IL6-mediated tumor 
progression. Addressing this will increase our understanding of the role of JNK in ErbB2-driven breast 
cancer and reveal a potentially new mechanism by which JNK functions in tumor progression.  
Additionally, I began the development of a mouse model that will allow us to investigate the role 
of JNK in macrophage polarization as an alternative mechanism by which JNK regulates ErbB2-driven 
breast cancer. In addition to promoting STAT3-dependent tumor growth, IL6 can indirectly drive 
tumorigenesis by promoting expression of the IL4 receptor in macrophages, triggering STAT6-mediated 
macrophage polarization towards the pro-tumorigenic M2 phenotype (10, 11). Unlike classically 
activated M1 macrophages, which promote inflammation and anti-tumor immunity, alternatively 
activated M2 macrophages function in immunosuppression and metastasis and correlate with advanced 
stages of breast cancer (12, 13). Further evidence supporting a role for the JNK pathway in macrophage 
polarization includes a recent study suggesting that JunB, a downstream JNK target and component of 
the AP-1 complex, plays a crucial role in the induction of M2 macrophage polarization in human alveolar 
macrophages (13). I hypothesize that activation of the JNK signaling pathway induces IL6-dependent 
macrophage polarization towards the pro-tumorigenic M2 phenotype. Addressing this hypothesis will 
determine for the first time whether JNK functions in regulating macrophage polarization within the 
tumor microenvironment, offering a potentially new mechanism by which JNK can promote ErbB2-
driven breast cancer.   
Determining the role of JNK in ErbB2-mediated breast cancer will have direct therapeutic 
relevance, as targeting JNK has the potential to inhibit ErbB2-driven breast cancer and other IL6-
mediated diseases. Investigating the underlying mechanisms by which JNK functions in ErbB2-positive 
breast cancer can also offer new molecular targets and further contribute to effective drug design.    
 
 
MATERIALS AND METHODS 
Mice 
The transgenic MMTV-NIC mouse model (JNKWT) contains a transgene expressing the mouse 
mammary tumor virus long terminal repeat (MMTV-LTR) promoter, followed by a constitutively active 
form of ErbB2 (Neu), an internal ribosome entry site (IRES), and Cre recombinase (Cre), or NIC 
(Figure 1a). The MMTV-LTR promoter ensures mammary cell-specific gene expression of ErbB2. The 
presence of an IRES site drives translation of Cre and ensures co-expression of Neu and Cre from 
the same bicistronic transcript. Due to the presence of Cre recombinase, this tumor mouse model can 
be crossed with any floxed transgenic mouse to induce mammary cell-specific deletion of a target-of-
interest, such as Jnk1/2 in this case. Once floxed Jnk1/2 mice are successfully backcrossed to an 
FVB background, they will be crossed to the MMTV-NIC mouse model to induce mammary-specific 
deletion of Jnk1/2, generating a JNKKO breast tumor model. To confirm the presence of the MMTV-
NIC transgene in new litters, mice were genotyped by PCR analysis of genomic DNA to detect Cre 
recombinase. JNKWT or MMTV-NIC mice were palpated weekly starting at 15 weeks of age. Tumors 
were measured using a caliper and mice were sacrificed once tumors reached 1 cm in diameter. 
MMTV-NIC mice were obtained from Dr. William J. Muller at McGill University. 
NuTRAP mice were obtained from Dr. Evan Rosen at Beth Israel Deaconess Medical Center.  
Backcrossing  
To generate the JNKKO (Jnk1loxP/loxPJnk2loxP/loxP) MMTV-NIC tumor model, Jnk1loxP/loxPJnk2loxP/loxP 
C57BL/6J mice were first backcrossed to the FVB NJ background for five generations. 
Jnk1loxP/+Jnk2loxP/+ FVB NJ mice were then crossed to MMTV-NIC FVB NJ mice, getting one step 
closer to generating JNKKO MMTV-NIC FVB NJ mice. (Future crosses will be performed and 
completed by other members of the lab.)   
Backcrosses were performed by creating breeders with FVB NJ (male or female) mice with Bl/6 mice 
of a desired genetic background for five or more generations.  
Analysis of tissue sections 
Tissues from JNKWT mice were fixed in 10% neutral buffer formalin for 18 hr, dehydrated, and 
embedded in paraffin. Tissue sections (7 um) were cut and stained with hematoxylin and eosin (H+E). 
The pathology of the tissues was then determined by Dr. David Garlick.  
Primary Cell Line Generation  
Breast tumors were dissected into DMEM/F12 media supplemented with 1% penicillin streptomycin 
and 2.4% nystatin (Sigma Aldrich, cat# N1638). Tumors were washed in phosphate-buffered saline 
and minced using a sterilized razor blade. Minced tumors were then digested in high glucose (4.5 g/L) 
DMEM media supplemented with 1% penicillin streptomycin and 2mg/mL collagenase (Sigma 
#C0130) for 2-3 hr rotating in 37˚C. Cells were centrifuged at 1000 RPM for 5 min and washed five 
times with 10 mL of PBS supplemented with 5% fetal bovine serum. Tumor cells were resuspended in 
DMEM/F12 media supplemented with 2% FBS and 1% penicillin streptomycin. Cells were then plated 
on collagen I Rat Tail (Gibco Life Technologies, cat# A10483-01).   
TRAP RNA Isolation 
Dounce homogenization and RNA isolation of inguinal fat (100mg) from Nutrap+/- Adipoq-Cre+ Bl/6 
male mice, fed either a chow or high fat diet for 16 weeks, was performed as previously described by 
Roh et al (14). Tissues were dounce homogenized in 4 mL of homogenization buffer (50mM Tris, pH 
7.5, 12mM MgCl2, 100mM KCl, 1% NP-40, 100ug/ml cycloheximide, 1 mgl/ml sodium heparin, 2mM 
DTT, 0.2units/ul RNasin, 1x Complete EDTA-free protease inhibitor). Anti-GFP antibody (Abcam, cat# 
ab290) at 5ug/mL was used to pre-coat Protein G dynabeads (Life Technologies, cat# 10003D). The 
Qiagen Micro RNeasy kit (Qiagen, cat# 74004) was used following incubation of homogenates with 
dynabeads and samples were resuspended in diH2O.   
RNA Sequencing 
Following TRAP RNA Isolation, RNA quality was determined using the Agilent Bioanalyzer and 
samples (at 1ug or greater) with a Rin value of 7 or higher were submitted for RNA sequencing to the 
BioMicro Center and samples were run on the NextSeq sequencer. RNA sequence analysis was 
performed by Yvonne Edwards (UMMS PMM Bioinformatics Core).  
 
RESULTS 
To define the role of JNK in ErbB2-driven breast cancer 
progression, I utilized the cre/loxP recombination system 
to begin the generation of ErbB2-driven breast cancer 
mouse models with either wild-type (JNKWT) or JNK-
deficient mammary cells (JNKKO). To generate a control 
JNKWT tumor model, the MMTV-NIC breast tumor mouse 
model, as described in Figure 1a, was crossed to wild-type 
FVB mice (Jnk1+/+Jnk2+/+). The MMTV-NIC or JNKWT mouse 
model constitutively expresses ErbB2 (or Neu) and results in 
spontaneous breast tumor formation (15, 16). To create an 
ErbB2-driven breast cancer mouse model with JNK-deficient 
mammary cells, MMTV-NIC mice will be crossed to mice 
expressing floxed Jnk1 and Jnk2 alleles 
(Jnk1LoxP/LoxPJnk2LoxP/LoxP), as shown in Figure 1b. Because the 
JNK1 and JNK2 proteins display functional 
redundancy, deletion of both Jnk1 and Jnk2 genes 
is essential for understanding the role of the JNK 
pathway in tumor development (17).  
To date, I have confirmed that the JNKWT (MMTV-
NIC) model develops breast tumors in line with the 
published literature (15,16). JNKWT mice developed 
palpable breast tumors at an average age of 138 
days, similar to the published data of 146 days 
(n=8). The breast tumors from JNKWT mice were 
characterized as multicentric mammary gland adenocarcinomas. The morphology of the tumors was 
consistent between JNKWT mice having a nodular, solid pattern, a low mitotic index, and a fairly well 
Figure 1. The MMTV-NIC breast tumor model and JNKKO v JNKWT 
breast tumor models. A) The transgenic MMTV-NIC mouse model 
expresses a constitutively active form of ErbB2 (Neu), an internal ribosome 
entry site (IRES), and Cre recombinase (Cre). This NIC transgene is 
regulated by the mouse mammary tumor virus long terminal repeat (MMTV-
LTR) promoter, which ensures mammary cell-specific gene expression. 
The presence of an IRES site drives translation of Cre and ensures co-
expression of Neu and Cre from the same bicistronic transcript.  B) General 
workflow and breeding scheme for JNKWT and JNKKO tumor models. +/+ 
indicates homozygous wild-type alleles. Yellow mass represents mammary 
tumor.   
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differentiated phenotype. In addition, 29% (2 out of 7) JNKWT mice had lung metastases. Previous 
characterization of the MMTV-Neu model containing the same transgene as the MMTV-NIC model 
showed that 60% (3 out of 5) mice had lung metastases (16). The difference in the percentage of 
mice that develop lung metastases may be attributed to low mice numbers in both studies. 
Additionally, previous characterization of lung metastases was performed 30-60 days after tumors 
were first palpable. In this study, lungs were harvested once original tumors reached 1 cm in diameter 
or greater; from the time the tumors were first palpable to when tumors and lungs were harvested 
ranged from 7-22 days. Thus, it is possible that fewer mice had developed lung metastases in this 
study, given the earlier timepoint at which tumors and organs were harvested. Previous 
characterization had shown that in addition to the lungs, expression of the MMTV-NIC transgene was 
also upregulated in the salivary glands and to a lesser extent, in the pancreas (15,16). I therefore, 
also harvested salivary glands and pancreas to determine if any metastases had occurred in these 
tissues. Consistent with the published literature, no metastases were seen in the pancreas or salivary 
glands of the JNKWT mice (15,16). Figure 2 shows representative images of breast tumors prior to 
dissection and H+E stained cross sections of breast tumors and lung metastases.  
To generate JNKKO mice, Jnk1LoxP/LoxPJnk2LoxP/LoxP mice had to first be backcrossed from a Bl/6 
background to an FVB background, given that ErbB2-driven breast tumors do not develop 
spontaneously under a Bl/6 
background (18). To date, I 
have successfully crossed 
Jnk1LoxP/+Jnk2LoxP/+ mice with 
FVB mice for five generations. I 
have also generated one 
breeder using a MMTV-NIC 
mouse and a Jnk1LoxP/+Jnk2LoxP/+ 
mouse under the FVB 
background. (Downstream 
generation of the JNKKO mice 
will be performed by other 
members of the lab.) Once 
JNKKO mice are successfully 
generated, tumor development 
and survival can be compared 
between JNKKO and JNKWT 
mice.  
To determine whether JNK 
regulates ErbB2-driven 
proliferation by an IL6-
dependent mechanism, IL6 
RNA levels in the tumor cells of 
JNKWT and JNKKO mice can be 
compared (once the mouse 
models are fully developed). To 
allow for the downstream 
analysis of RNA expression in 
tumor cells specifically, I 
utilized the Nutrap+/- (Nuclear 
tagging and Translating 
Figure 2. Representative images of JNKWT (MMTV-NIC) mice. A) Image of JNKWT mouse at 
24 weeks-old. Breast tumors can arise from any of the 10 mammary glands (depicted by black 
arrows). Mice were taken down once any one of the tumors reached >1 cm in diameter as 
measured by caliper. B) Representative image of H+E stained 7um cross-section of a breast 
tumor from JNKWT mouse, where normal mammary gland elements, the mammary fat pad, and 
tumor vascular invasion surrounding the tumor are marked. C) H+E stained 7um cross-section of 
lung tissue from a JNKWT mouse, where lung metastases are marked by black arrows.   
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Ribosome Affinity Purification) mouse model developed by Dr. Evan Rosen (14). This mouse model 
allows for simultaneous isolation of mRNA and nuclei from any cell type in the presence of Cre 
recombinase. In the presence of Cre, a Stop codon is excised in the Nutrap transgene, allowing co-
expression of the BirA biotin ligase, a biotin ligase recognition sequence (BLRP) fused to mCherry-
RanGAP1 (a nuclear pore protein), and EGFP-L10a (a 60S ribosomal protein). BirA biotinylates the 
BLRP domain of the mCherry-RanGAP1 protein, allowing for easy downstream purification of biotin-
labeled nuclei and subsequent DNA sequencing; EGFP-L10a allows for the affinity purification of 
ribosomes and hence, isolation of actively-translating RNA and downstream RNA sequencing. 
Crossing the Nutrap+/- mice to the JNKKO and JNKWT mice will allow for ribosome-labeling of only 
mammary cells and hence, downstream mRNA sequencing of specifically breast tumor cells.  
In order to utilize the Nutrap+/- mice in an ErbB2-driven breast cancer mouse model, I had to first 
backcross the mice from a Bl/6 background to an FVB background. To date, I have successfully 
backcrossed the Nutrap+/- mice up to 5 generations under the FVB background. These mice are now 
available to be crossed to the JNKWT and JNKKO mice.  
As a proof-of-concept experiment to demonstrate that the TRAP RNA isolation works as previously 
described, I performed TRAP RNA isolation on the inguinal fat of Nutrap+/- Adipoq-Cre+ Bl/6 male mice 
fed either a chow diet or high fat diet for 16 weeks. For unknown reasons, E. coli contamination was 
present in the chow diet group, which may have been due to contaminations from other samples, as 
sequencing was run with multiple samples per lane. There was lower than expected read mapping 
rates to the mouse reference, with 32-42% mapping in the chow diet group and 72-77% mapping in 
the high fat diet group. Despite this, differentially expressed genes were determined, as shown in 
Table 1, although this experiment should be repeated for further validation.   
To test whether JNK in ErbB2-driven breast cancer plays a role in macrophage polarization, tumors 
from JNKWT and JNKKO mice (once models are fully developed) can be harvested and flow cytometry 
can be used to determine the population sizes of M1 and M2 macrophages by gating on M1 markers, 
such as CD38, Gpr18, and Fpr2, and M2 markers, including Egr2 and c-Myc (19). Macrophage 
phenotypes can be further characterized by sorting M1 and M2 populations by FACS and using qPCR 
to measure expression levels of known M1 macrophage-associated genes, including Cd11c, Il1β, 
Nos1, Tnfα, and M2 macrophage-associated genes Mgl1, Mrc1, Ccl17, and Ccl22 (20).  
 
DISCUSSION  
Generating the JNKWT and JNKKO mice as described 
here, will allow us to determine the role of the JNK 
pathway in ErbB2-driven breast cancer. To date, I have 
validated the JNKWT mice and have shown that the tumor 
characteristics are similar to those previously published. 
The JNKKO mice are currently being generated, where 
Jnk1LoxP/+Jnk2LoxP/+ mice have been successfully 
backcrossed five generations into an FVB background 
and are undergoing crosses with MMTV-NIC mice. Once 
JNKKO mice are generated, tumor progression and tumor 
characteristics of the JNKWT and JNKKO mice can be 
compared to determine the role of JNK in ErbB2-driven 
breast cancer and any differences in macrophage 
polarization can also be determined.  
The upstream JNK regulators, MKK4 and MAP3K1, are 
frequently mutated in various forms of breast cancer; 
however, JNK mutations are not as commonly found (21, 
22, 23). Because MKK4 and MAP3K1 may regulate other 
downstream proteins besides JNK that function in 
tumorigenesis, JNK deletion alone may not completely 
abrogate tumor growth. Thus, I believe that the JNKKO mice described in this study will delay tumor 
progression but may not result in complete tumor abrogation.   
In this study, I have also backcrossed Nutrap+/- mice for five generations into an FVB background. Once 
JNKKO mice are available, Nutrap+/- mice can be crossed with both JNKKO and JNKWT mice and allow 
for easy RNA isolation of tumor cells and downstream RNA sequencing. This will allow us to determine 
whether the JNK pathway functions through an IL6-dependent mechanism, while also giving us a 
comprehensive analysis of differences in actively-translating RNA, which may reveal other previously 
unknown mechanisms by which JNK functions in ErbB2-driven breast cancer. I believe that in addition 
to augmentations in the IL-6 pathway, JNK deletion will also result in changes in other inflammatory 
cytokines regulated by JNK, such as IL-1 and TNFa. Changes in the expression of apoptosis regulators 
is also likely, as downstream targets of JNK also include BIM, BAD, Mcl1, and the Bcl2 family of proteins 
(17, 24).  
In addition to the questions proposed in this work, another underlying problem that remains 
unaddressed is which cell type JNK plays the greatest role in during breast cancer progression. To date, 
a direct and rigorous comparison of the role of JNK in tumor cells, versus macrophages, has not been 
performed. To determine the role of JNK in macrophages, as opposed to tumor cells, during ErbB2-
driven breast cancer, a LyzCre+/- Nutrap+/- JNKWT and JNKKO tumor mouse model can be generated 
(Figure 3). To do this, LyzCre+/- mice have to first be backcrossed from a Bl/6 background to an FVB 
background. To date, I have crossed the LyzCre+/- mice to FVB mice for four generations, and the mice 
require one more FVB cross before they can be used to generate a breast tumor model. Although 
addition of the Nutrap gene is not necessary to determine the role of JNK in macrophages on ErbB2-
Figure 3. Generation of a mouse model to test the role of 
macrophage-specific JNK in ErbB2-driven breast cancer 
progression and survival.  
induced tumor progression, its presence allows for downstream RNA and DNA analysis of tumor-
associated macrophages in JNKKO and JNKWT mice. Once these mice are generated, tumor progression 
and survival can be compared between tumor-specific JNKKO mice and macrophage-specific JNKKO 
mice. Because JNK has been shown to also play a major role in IL6 regulation in macrophages and 
macrophage polarization, I believe that JNK functions in both tumor cells, as well as tumor-associated 
macrophages, to promote tumor progression in ErbB2-driven breast cancer (20). Defining the role of 
JNK in tumor cells as compared to macrophages will better inform us on which cell type to target for 
therapeutic purposes.  
In addition to the Jnk1LoxP/+Jnk2LoxP/+, Nutrap+/-, and LyzCre+/- mice, I have also started Bl/6-to-FVB 
backcrosses of Il6LoxP/LoxP, Mkk4+/-, and Mkk7+/- mice for future experiments to determine the role of 
these other JNK pathway proteins on breast cancer progression. Because mutations in MKK4 and 
MKK7 are seen more frequently in breast cancer than JNK mutations, I hypothesize that deletion of 
MKK4 and MKK7 will result in a greater delay of tumor progression than JNK deletion (21, 22, 23). 
Because IL-6 expression can be induced through JNK-independent mechanisms, such as through p38 
pathway activation, I believe that Il6 deletion in the ErbB2 mouse model will inhibit tumor growth to a 
greater extent than JNK deletion.    
Lastly, I would like to address my thoughts on the varying, and sometimes contradicting roles of JNK 
seen in different cellular contexts. I believe that the varying functions of the JNK pathway in different 
cancer models can be attributed, in part, by differences in JNK isoform-specific functions. It is important 
to note that there are three genes: jnk1, jnk2, and jnk3, which can encode a total of ten different isoforms 
of JNK proteins (25). Previous data have shown that different JNK isoforms have varying and opposing 
functions. For example, experiments in colon cancer reveal that knockdown of JNK1α1 leads to 
increased cell death, whereas knockdown of JNK1α2 and JNK1β2 causes decreased apoptosis (26). 
To define the role of individual JNK isoforms, future experiments targeting isoform-specific exons in the 
three JNK genes can be performed to selectively knock-out specific JNK isoforms in tumor models.  
Furthermore, I believe that JNK isoforms have distinct functions because of differences in their 
substrate binding preferences. Support for this hypothesis comes from previous studies showing that 
all ten isoforms differ in their binding to ATF-2, c-Jun, and Elk-1 transcription factors (25). However, 
JNK isoform-specific substrates remain uncharacterized. Further studies must be conducted to 
determine the substrates of specific JNK isoforms. In the future, it will be important to determine any 
differences in JNK isoform expression between breast cancer models, as JNK isoforms can have 
varying downstream targets, which may contribute to the opposing biological outcomes of JNK 
deletion seen in past studies. Because JNK proteins are expressed in multiple tissue types and serve 
various biological functions, defining the distinct functions and substrates of individual isoforms will be 
imperative in the therapeutic targeting of the JNK pathway in cancer.   
 
Additionally, it is possible that the discrepancy in the function of JNK in various cancer types is caused, 
not by the mere presence or absence of JNK, but by JNK protein dynamics. Changes in JNK dynamics, 
defined as the duration of activation, leads to opposing downstream effects in fibroblasts and T cells. 
Chronic JNK stimulation in T cells and fibroblasts results in apoptosis, which directly opposes the cell 
survival effects of transient JNK activation (27, 28). To determine whether JNK dynamics play a role in 
breast cancer development, we can induce acute inhibition of JNK in the ErbB2 breast cancer mouse 
model by injection of a JNK inhibitor for several timepoints throughout tumor development; overall 
survival and tumor development from this model can be compared to chronic JNK deletion as present 
in the JNKKO model described in this work. Future studies will be required to determine how differences 
in the dynamics of JNK expression affect varying cancer models. If distinct JNK protein dynamics in fact 
define the downstream biological effect, it is possible to use these differences in protein dynamics as a 
screening tool to understand whether cancer patients will benefit from JNK inhibition or JNK activation.  
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